A former Pfizer manufacturing facility in Indiana, US, looks set for a new lease of life after technology company NantWorks …
Once predicted to be a blockbuster, inhaled insulin product Exubera is to be abandoned by Pfizer because of poor sales.Exubera …
Diabetes patients who are genuinely needle-phobic will be among the few to be given Pfizer’s inhaled insulin product Exubera on …
Pfizer has paid $1.3 billion to buy out its marketing partner’s stake in new inhaled diabetes drug Exubera.The US company …


